Effect of Mirtazapine Versus Placebo in Reversing Anorexia in Non-small Cell Lung cáncer Patients
Status:
Recruiting
Trial end date:
2022-01-29
Target enrollment:
Participant gender:
Summary
The realization of this project will generate an important advance in knowledge regarding one
of the most important comorbidities in cancer patients: malnutrition.
Currently, comprehensive treatments of cancer patients recognize the importance of the
assessment of nutritional status, and the impact it has on the prognosis, quality of life and
toxicity generated by cancer treatment. Due to this, it is imperative to offer diagnostic
tools that identify patients in a timely manner and, in addition to this, offer therapeutic
strategies for the improvement of nutritional status, in an adjuvant manner to their
oncological treatment.
It is widely recognized that the cachexia-anorexia syndrome (CACS) is present in 30 to 80% of
cases in cancer patients and this proportion increases as the disease progresses, with weight
loss being a powerful predictor of shorter survival. Unfortunately, current therapies
available to treat anorexia and / or cancer-associated cachexia offer only partial results,
mainly because the intervention is late and the development of an earlier and more effective
intervention is still sought. Mirtazapine has recently gained attention not only because of
its antidepressant effect, but also because of its potential benefit in patients with
anorexia and weight loss, recently reported in a phase II study. Therefore, it is important
to continue its evaluation through a randomized, double-blind clinical trial in which the
effect of mirtazapine is compared and it is determined if it is superior compared to placebo
to increase appetite in patients with NSCLC who present with anorexia.
This type of strategy is a relevant therapeutic option in those patients in whom nutritional
counseling by itself is not sufficient to counteract the damage caused by anorexia and to
cope with or prevent the development of cachexia.